Sorafenib and Everolimus in Advanced Clear Cell Renal Carcinoma: A Phase I/II Trial of the SCRI Oncology Research Consortium

被引：24

作者：

Hainsworth, John D. ^{[1
,2
]}

Waterhouse, David M. ^{[1
,3
]}

Penley, William C. ^{[1
,2
]}

Shipley, Dianna L. ^{[1
,2
]}

Thompson, Dana S. ^{[1
,2
]}

Webb, Charles D. ^{[4
]}

Greco, F. Anthony ^{[1
,2
]}

机构：

[1] Sarah Cannon Res Inst, Nashville, TN 37203 USA

[2] Tennessee Oncol PLLC, Nashville, TN USA

[3] Oncol Hematol Care Inc, Cincinnati, OH USA

[4] Baptist Hosp East, Louisville, KY USA

来源：

CANCER INVESTIGATION | 2013年 / 31卷 / 05期

关键词：

Angiogenesis; Clinical trials; Kidney; Ureter; Urethra & Penis Cancer; INTERFERON-ALPHA; MAMMALIAN TARGET; BEVACIZUMAB; SUNITINIB;

D O I：

10.3109/07357907.2013.789900

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Purpose: To evaluate the feasibility and efficacy of sorafenib and everolimus in renal cell carcinoma (RCC). Methods: Patients with advanced RCC and <= 1 previous targeted therapy were treated. Results: Maximum tolerated doses were sorafenib 200 mg PO BID, everolimus 35 mg PO once weekly. Dose-limiting toxicity was hand-foot syndrome. The response rate was 13%; median PFS was 5.45 months (95% CI: 3.8-7.6). Skin toxicity, fatigue, hypertension, proteinuria, and mucositis (usually Grade 2) were common. Conclusions: Fifty percent doses of sorafenib and everolimus were required when these drugs were combined. No increase in efficacy was suggested; toxicity was modestly increased.

引用

页码：323 / 329

页数：7

共 16 条

[1] Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors [J].

Bergers, G ;

Song, S ;

Meyer-Morse, N ;

Bergsland, E ;

Hanahan, D .

JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (09) :1287-1295

[2] Can the combination of temsirolimus and bevacizumab improve the treatment of metastatic renal cell carcinoma (mRCC)? Results of the randomized TORAVA phase II trial [J].

Escudier, B. J. ;

Negrier, S. ;

Gravis, G. ;

Chevreau, C. ;

Delva, R. ;

Bay, J. ;

Geoffrois, L. ;

Lagouffe, E. ;

Blanc, E. ;

Ferlay, C. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

[3] Sorafenib in advanced clear-cell renal-cell carcinoma [J].

Escudier, Bernard ;

Eisen, Tim ;

Stadler, Walter M. ;

Szczylik, Cezary ;

Oudard, Stephane ;

Siebels, Michael ;

Negrier, Sylvie ;

Chevreau, Christine ;

Solska, Ewa ;

Desai, Apurva A. ;

Rolland, Frederic ;

Demkow, Tomasz ;

Hutson, Thomas E. ;

Gore, Martin ;

Freeman, Scott ;

Schwartz, Brian ;

Shan, Minghua ;

Simantov, Ronit ;

Bukowski, Ronald M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (02) :125-134

[4] Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival [J].

Escudier, Bernard ;

Bellmunt, Joaquim ;

Negrier, Sylvie ;

Bajetta, Emilio ;

Melichar, Bohuslav ;

Bracarda, Sergio ;

Ravaud, Alain ;

Golding, Sophie ;

Jethwa, Sangeeta ;

Sneller, Vesna .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2144-2150

[5] Phase I Trial of Bevacizumab Plus Escalated Doses of Sunitinib in Patients With Metastatic Renal Cell Carcinoma [J].

Feldman, Darren R. ;

Baum, Michael S. ;

Ginsberg, Michelle S. ;

Hassoun, Hani ;

Flombaum, Carlos D. ;

Velasco, Susanne ;

Fischer, Patricia ;

Ronnen, Ellen ;

Ishill, Nicole ;

Patil, Sujata ;

Motzer, Robert J. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1432-1439

[6] Phase II Trial of Bevacizumab and Everolimus in Patients With Advanced Renal Cell Carcinoma [J].

Hainsworth, John D. ;

Spigel, David R. ;

Burris, Howard A., III ;

Waterhouse, David ;

Clark, Bobby L. ;

Whorf, Robert .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2131-2136

[7] Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma [J].

Hudes, Gary ;

Carducci, Michael ;

Tomczak, Piotr ;

Dutcher, Janice ;

Figlin, Robert ;

Kapoor, Anil ;

Staroslawska, Elzbieta ;

Sosman, Jeffrey ;

McDermott, David ;

Bodrogi, Istvan ;

Kovacevic, Zoran ;

Lesovoy, Vladimir ;

Schmidt-Wolf, Ingo G. H. ;

Barbarash, Olga ;

Gokmen, Erhan ;

O'Toole, Timothy ;

Lustgarten, Stephanie ;

Moore, Laurence ;

Motzer, Robert J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (22) :2271-2281

[8] NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].

KAPLAN, EL ;

MEIER, P .

JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481

[9] Hypoxia-inducible factor 1α is regulated by the mammalian target of rapamycin (mTOR) via an mTOR signaling motif [J].

Land, Stephen C. ;

Tee, Andrew R. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2007, 282 (28) :20534-20543

[10] Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma [J].

Motzer, RJ ;

Bacik, J ;

Schwartz, LH ;

Reuter, V ;

Russo, P ;

Marion, S ;

Mazumdar, M .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (03) :454-463

← 1 2 →